Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Wegovy's launch in Thaliand comes nearly a month after Eli Lilly launched its obesity management drug Mounjaro in India at ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

A federal judge's ruling essentially blocks compound pharmacies from selling less-expensive, unapproved versions of Ozempic ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...